Astrazeneca (AZN) Common Equity (2009 - 2026)
Astrazeneca (AZN) posted quarterly Common Equity of $50.4 billion for Q2 2026, up 12.41% year-over-year from $44.8 billion in Q2 2025, and up 6.42% quarter-over-quarter from $47.3 billion in Q1 2026.
Astrazeneca (AZN) Common Equity (2009 - 2026) Analysis & Trends
Astrazeneca's Common Equity history runs 18 years deep, the most recent figure standing at $50.4 billion for Q2 2026.
- In Q2 2026, Common Equity rose 12.41% year-over-year to $50.4 billion; the TTM figure through Jun 2026 stood at $50.4 billion (up 12.41% YoY), while the FY2025 annual figure was $48.7 billion, up 19.2% from the prior year.
- Common Equity for Q2 2026 stood at $50.4 billion, up from $47.3 billion in the prior quarter.
- The five-year high for Common Equity was $50.4 billion in Q2 2026, with the low at $35.1 billion in Q3 2022.
- The 5-year median for Common Equity is $39.3 billion (2023), against an average of $40.6 billion.
- Peak annual rise in Common Equity reached 218.74% in 2022, while the deepest fall reached 11.6% in 2022.
- Astrazeneca's Common Equity stood at $37.1 billion in 2022, then grew by 5.69% to $39.2 billion in 2023, then advanced by 4.35% to $40.9 billion in 2024, then increased by 19.2% to $48.7 billion in 2025, then rose by 3.39% to $50.4 billion in 2026.
- Business Quant data shows AZN's Common Equity at $50.4 billion in Q2 2026, $47.3 billion in Q1 2026, and $48.7 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.91 Bn | 632.15 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 469.40 Bn | 462.83 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 375.75 Bn | 368.61 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.13 Bn | 295.44 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.65 Bn | 252.75 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.26 Bn | 222.27 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.12 Bn | 178.95 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.46 Bn | 147.76 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.21 Bn | 102.04 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 55.16 Bn | 47.78 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 50.37 Bn |
| Mar 31, 2026 | 47.33 Bn |
| Dec 31, 2025 | 48.72 Bn |
| Sep 30, 2025 | 45.89 Bn |
| Jun 30, 2025 | 44.81 Bn |
| Mar 31, 2025 | 41.04 Bn |
| Dec 31, 2024 | 40.87 Bn |
| Sep 30, 2024 | 40.72 Bn |
| Jun 30, 2024 | 39.51 Bn |
| Mar 31, 2024 | 37.45 Bn |
| Dec 31, 2023 | 39.17 Bn |
| Sep 30, 2023 | 37.22 Bn |
| Jun 30, 2023 | 37.42 Bn |
| Mar 31, 2023 | 35.79 Bn |
| Dec 31, 2022 | 37.06 Bn |
| Sep 30, 2022 | 35.13 Bn |
| Jun 30, 2022 | 35.95 Bn |
| Mar 31, 2022 | 36.34 Bn |
| Dec 31, 2021 | 39.29 Bn |
| Sep 30, 2021 | 39.74 Bn |